Showing 7481-7490 of 8834 results for "".
- Done Deal: AbbVie Completes Acquisition of Allerganhttps://practicaldermatology.com/news/done-deal-abbvie-completes-acquisition-of-allergan/2460389/AbbVie completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. In connection with the closing of the transaction, the AbbVie Board of Directors has elec
- SciBase Receives FDA Approval for Nevisense 3.0https://practicaldermatology.com/news/scibase-receives-fda-approval-for-nevisense-30/2460388/The FDA has approved SciBase AB's Nevisense 3.0, the third generation of their Nevisense system for early melanoma detection. Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in
- Accure Laser Gets CE Mark for Acne Treatmenthttps://practicaldermatology.com/news/accure-laser-gets-ce-mark-for-acne-treatment/2460386/Accure Acne, Inc. now has a European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris. The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands. Fo
- Industry Responds to COVID-19: Allergan Foundation Doubles Down on COVID-19 Donationshttps://practicaldermatology.com/news/industry-responds-allergan-foundation-doubles-down-on-covid-19-donations/2460385/The Allergan Foundation fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic, doubling their COVID-19 donations to date, raising the total to $4 million. The donations are dedicated to 57 organ
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- 2020 RealSelf Sun Safety Report: Majority of Americans Don’t Use Sunscreen Dailyhttps://practicaldermatology.com/news/realself-sun-safety-report-majority-of-americans-dont-use-sunscreen-daily/2460381/The recently released 2020 RealSelf Sun Safety Report found that 62 percent of Americans use anti-aging products as part of their daily skincare routine, but only 11 percent wear sunscreen daily and 46 percent never wear
- Calling All Heroes: Cutera Seeks to Honor COVID-19 Championshttps://practicaldermatology.com/news/calling-all-heroes-cutera-seeks-to-honor-covid-19-champions/2460380/From physicians going back to the ER and conducting hospital rounds to supporting food depositories and shelters, to doctors donating personal protective equipment, ventilators, and office facilities as needed during the COVID-19 global pandemic, Cutera wants to shine a spotlight on its customers
- Cutera's TruSculpt Flex Wins 2020 Good Housekeeping Awardhttps://practicaldermatology.com/news/cuteras-trusculpt-flex-wins-2020-good-housekeeping-award/2460373/Congrats! Cutera’s truSculpt flex won a Good Housekeeping 2020 Beauty Award Winner for Ultimate Body Product. truSculpt flex is FDA-cleared for the improvement of abdominal tone, strengthening of the abdominal muscles, and development of a firmer abdomen. It is also cleared for th
- Urgent: CMS Extends MIPS Extreme and Uncontrollable Circumstances Exception Application Until 4/30/2020https://practicaldermatology.com/news/urgent-cms-extends-mips-extreme-and-uncontrollable-circumstances-exception-application/2460369/The Centers for Medicare & Medicaid Services (CMS) re-opened the 2019 MIPS Extreme and Uncontrollable Circumstances Exception Application to individuals, groups, and virtual groups, including those who have already submitted data, due to the 2019 Novel Coronavirus (COVID-19) pandemi
- COVID-19 By the Numbers: April 28 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-28-edition/2460365/The CDC now lists nine potential symptoms of COVID-19, though cough and shortness of breath or difficulty breathing remain hallmarks of the disease. CDC says individuals may have COVID-19 if they experience these two symptoms plus at least two of the following: Fever